SCHEMBL3887063

SCHEMBL3887063

COc1cccc(S(=O)(=O)c2ccnc3[nH]cc(CCNC(=O)O)c23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.41
FGFR4 P22455 2/20 0.41
MTNR1A P48039 4/20 0.40
MTNR1B P49286 3/20 0.40
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.40
TRPV1 Q8NER1 1/20 0.40
NAMPT P43490 2/20 0.40
LRRK2 Q5S007 1/20 0.39
SNCA P37840 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LTA4H P09960 1/20 0.39
PLA2G2A P14555 1/20 0.39
PTGER3 P43115 1/20 0.39
FGFR1 P11362 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP1A1 P04798 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658530 0.84 FGFR4 (0.39) FGFR4MTNR1BPTGDR2NAMPTLRRK2
SCHEMBL3889634 0.84 HTR2A (0.44) FGFR4MTNR1AMTNR1BLRRK2KMT2A
SCHEMBL3889087 0.71 HTR2A (0.43) MTNR1AMTNR1BALDH1A1KMT2AKDM4E
SCHEMBL3899516 0.69 HTR1A (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2036199 0.69 MTNR1A (0.61) FGFR4MTNR1AMAPTTRPV1SNCA
SCHEMBL3887065 0.69 HTR6 (0.48) MTNR1AMTNR1BPTGDR2HTR1A
SCHEMBL3886084 0.68 HTR6 (0.52) MTNR1AMTNR1BHTR1A
SCHEMBL4125767 0.67 NFE2L2 (0.39) MTNR1BMAPTGAAPTGDR2NAMPT
SCHEMBL4131739 0.67 MEP1B (0.42) MTNR1BALDH1A1PTGDR2NAMPT
SCHEMBL4120655 0.66 NFE2L2 (0.39) MTNR1BGAANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585876-B2 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2009-09-08 US disclosed
EP-1456206-B1 AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2008-05-21 EP disclosed
US-20080114023-A1 AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2008-05-15 US disclosed
US-6800640-B2 ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS WYETH 2004-10-05 US disclosed
US-20030171395-A1 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands WYETH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171395-A1 Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A FAAH 316/4885FGFR4 3798/4885MTNR1A 59/4885
US-20080114023-A1 AZAINDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS HTR6, HTR5A, HTR7 FAAH 350/4885FGFR4 3748/4885MTNR1A 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.